Select Language
Coagulation factor XI
Coagulation factor XI Overview
| English Name | Coagulation factor XI | Approved Drugs | 2 |
| Drugs in Clinical Trials | 30 | Target Synonym | EC 3.4.21，EC:3.4.21.27，FXI，F11，PTA，Coagulation Factor XI，Plasma Thromboplastin Antecedent，EC 3.4.21.27，Factor XI，Coagualtion Factor XI |
| Highest Development Stage | Approved | ||
| English Name | Coagulation factor XI |
| Target Synonym | EC 3.4.21，EC:3.4.21.27，FXI，F11，PTA，Coagulation Factor XI，Plasma Thromboplastin Antecedent，EC 3.4.21.27，Factor XI，Coagualtion Factor XI |
| Approved Drugs | 2 |
| Drugs in Clinical Trials | 30 |
| Highest Development Stage | Approved |
Coagulation factor XI Product List
- Product Category
Protein (2)
- Product Status
Launched (2)
- Species
Human (1)Rhesus macaque (1)
- Tag
His Tag (2)
- Conjugate
Unconjugated (2)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
FXI-H52H5 |  Human | HEK293 | Human Coagulation factor XI / FXI Protein, His Tag (active enzyme) |  |  |  |
FXI-C52H3 |  Rhesus macaque | HEK293 | Rhesus macaque Coagulation factor XI Protein, His Tag (Pro-form) |  | | |
Total: 2
- 1
Coagulation factor XI Background
This protein is present in plasma as a zymogen, which is a unique plasma coagulation enzyme because it exists as a homodimer consisting of two identical polypeptide chains linked by disulfide bonds. During activation of the plasma factor XI, an internal peptide bond is cleaved by factor XIIa (or XII) in each of the two chains, resulting in activated factor XIa, a serine protease composed of two heavy and two light chains held together by disulfide bonds. This activated plasma factor XI triggers the middle phase of the intrisic pathway of blood coagulation by activating factor IX. Defects in this factor lead to Rosenthal syndrome, a blood coagulation abnormality
Coagulation factor XI Synonyms
Coagulation factor XI,FXI,PTA,F11
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Asundexian | BAY-2433334 | Phase 3 Clinical | Bayer AG | Atrial Fibrillation; Embolism; Hepatic Insufficiency; Ischemic Attack, Transient; Ischemic Stroke; Myocardial Infarction; Stroke; Thromboembolism | Details |
| Cenvacibart | REGN7508 | Phase 3 Clinical | Regeneron Pharmaceuticals Inc | Atrial Fibrillation; Peripheral Arterial Disease; Thrombosis; Venous Thromboembolism | Details |
| Milvexian | BMS-986177; JNJ-70033093; JNJ-3093 | Phase 3 Clinical | Bristol-Myers Squibb Company | Acute Coronary Syndrome; Atrial Fibrillation; Contraception; Coronary Thrombosis; Embolism; Ischemic Attack, Transient; Ischemic Stroke; Kidney Failure, Chronic; Renal Insufficiency; Stroke; Thromboembolism; Thrombosis | Details |
| SHR-2004 | SHR-2004 | Phase 3 Clinical | Beijing Suncadia Medicine Co Ltd | Arterial Thromboembolism; Atrial Fibrillation; Dyslipidemias; Thromboembolism; Thrombosis; Venous Thromboembolism; Venous Thrombosis | Details |
| Amrecibart | REGN-9933 | Phase 3 Clinical | Regeneron Pharmaceuticals Inc | Atrial Fibrillation; Peripheral Arterial Disease; Venous Thromboembolism | Details |
| Abelacimab | MAA-868; NOV-12 | Phase 3 Clinical | Novartis Pharma Ag | Atrial Fibrillation; Embolism; Neoplasms; Pulmonary Embolism; Stroke; Thromboembolism; Venous Thromboembolism; Venous Thrombosis | Details |
| EP-7041 | EP-7041; HSK-36273 | Phase 2 Clinical | Exithera Pharmaceuticals Inc | Blood Coagulation Disorders; Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Thrombocytopenia; Thromboembolism; Thrombosis | Details |
| Osocimab | BAY-1213790 | Phase 2 Clinical | Bayer AG | Kidney Diseases; Kidney Failure, Chronic; Thromboembolism | Details |
| IONIS-FXIRX | ISIS-404071; BAY-2306001; ISIS-FXIRX; FXI-ASO; IONIS-FXIRX; ISIS-416858 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Thrombosis; Venous Thromboembolism | Details |
| MK-2060 | MK-2060 | Phase 2 Clinical | Merck Sharp & Dohme Corp | Kidney Diseases; Kidney Failure, Chronic; Thromboembolism; Thrombosis | Details |
| SRSD-107 | SRSD-107; SRSD107 | Phase 2 Clinical | Sirius Therapeutics Inc | Arterial Thromboembolism; Cardiovascular Diseases; Coronary Artery Disease; Coronary Disease; Peripheral Arterial Disease; Thromboembolism; Thrombosis; Venous Thromboembolism | Details |
| RBD-4059 | RBD-4059; RBD4059; SR059; SR-059 | Phase 2 Clinical | Suzhou Ribo Life Science Co Ltd | Coronary Artery Disease; Coronary Disease; Kidney Failure, Chronic; Venous Thrombosis | Details |
| KN-060 | KN-060; KN060 | Phase 2 Clinical | Suzhou Alphamab Co Ltd | Essential Hypertension; Hypertension; Kidney Failure, Chronic; Obesity; Overweight; Thromboembolism | Details |
| Ir-CPI | BIOX-101; Ir-CPI | Phase 2 Clinical | Free University Of Brussels | Cerebral Hemorrhage | Details |
| Fesomersen | ION-957943; IONIS-FXI-LRx; BAY-2976217 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Nephrosis; Thromboembolism | Details |
| ONO-7269 | ONO-7269 | Phase 1 Clinical | Ono Pharmaceutical Co Ltd | Cerebral Infarction | Details |
| BAY-1831865 | AB-012; BAY-1831865 | Phase 1 Clinical | Aronora Inc | Thrombosis | Details |
| A-336 | A336; A-336 | Phase 1 Clinical | Klus Pharma | Thromboembolism | Details |
| A-186 | A-186 | Phase 1 Clinical | Sichuan Kelun Pharmaceutical Co Ltd | Thromboembolism | Details |
| BMS-262084 | BMS-262084 | Phase 1 Clinical | Bristol-Myers Squibb Company | Thrombosis | Details |
| ADX-626 | ADX-626 | Phase 1 Clinical | ADARx Pharmaceuticals Inc | Thrombosis | Details |
| SBK-013 | SBK013; SBK-013 | Phase 1 Clinical | Chengdu Shibeikang Biomedical Technology Co Ltd | Arterial Thromboembolism; Thromboembolism; Venous Thromboembolism | Details |
| XH-S002 | XH-S002; XHS002 | Phase 1 Clinical | Ischemic Attack, Transient; Stroke | Details | |
| BMS-986209 | BMS-986209 | Phase 1 Clinical | Bristol-Myers Squibb Company | Details | |
| NIP-003 | NIP003; NIP-003; CRB4101; CRB-4101 | Phase 1 Clinical | National Institutes Of Pharmaceutical Research And Development Co Ltd | Thromboembolism; Venous Thromboembolism; Venous Thrombosis | Details |
| Factor XIa Inhibitor (Bayer) | Factor XIa Inhibitor (Bayer) | Phase 1 Clinical | Bayer AG | Blood Coagulation Disorders | Details |
| SKB-336 | SKB-336 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Embolism; Thromboembolism | Details |
| SAL-0104 | SAL-0104; SAL0104 | Phase 1 Clinical | Suzhou Genemen Biotech Co Ltd | Cardiovascular Diseases; Embolism; Ischemic Attack, Transient; Myocardial Infarction; Stroke; Thrombosis; Venous Thromboembolism; Venous Thrombosis | Details |
| STP122G | STP-122G; STP122G | Phase 1 Clinical | Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd | Embolism and Thrombosis | Details |
| SHR2285 | SHR-2285 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Embolism; Thromboembolism; Thrombosis; Venous Thromboembolism | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Factor XI concentrate (factor XI deficiency), CSL Behring | Approved | Csl Behring Llc | Australia | Factor XI Deficiency | Csl Behring Llc | 2014-07-01 | Factor XI Deficiency | Details | ||
| Human coagulation Factor XI (LFB) | Approved | Lfb Biotechnologies Sas | Hemoleven | EU | Factor XI Deficiency | Lfb Biotechnologies Sas | 1999-07-01 | Factor XI Deficiency | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to: